MILAN—The investigative poly (ADPribose) polymerase (PARP) inhibitor iniparib (BSI-021) im proved not only progression-free survival (PFS) but also overall survival (OS) in the final analysis of a randomized phase 2 study, presented at the 35th European Society for Medical Oncology Congress by Joyce O’Shaughnessy, MD, of US Oncology and Baylor Sammons Cancer Center, Houston.
CHICAGO—Targeted intraoperative radiotherapy (TIR) for breast cancer, in which radiotherapy is confined to the area of the breast where the tumor has been removed, has been found to be as good as whole breast radiotherapy at reducing breast cancer recurrence. Most important, the new data presented at the 46th annual meeting of the American Society of Clinical Oncology showed TIR can be carried out in just one hospital visit.
As early as 3000 BC, descriptions can be found on Egyptian papyruses documenting reconstructive techniques used by priest doctors to restore altered appearances to normality. The upper echelons of Egyptian society placed great importance on appearance, and this seems to have been the stimulus for development of modern-day plastic surgery.
CHICAGO—Several new agents elicited excitement for the treatment of women with advanced breast cancer, including a novel cytotoxic agent that is the first to improve survival as mono therapy in this challenging patient population.
In an international study, patients with metastatic breast cancer refractory to numerous treatments lived 2.5 months longer when treated with eribulin mesylate, a synthetic analog of the novel halichondrin B family, versus single agents alone.
Lymphedema, an excess of fluid and protein caused by impaired lymph flow from the tissue, is a common and debilitating complication of cancer surgery and radiation treatment.1 Depending on which area and lymph nodes are affected, the areas of edema or swelling can be the arms, legs, head and neck, trunk, abdomen, or groin. Lymphedema is not a life-threatening condition but is one that has no cure.
For women with human epidermal growth factor receptor type 2 (HER2)-positive early breast cancer, delaying trastuzumab until chemotherapy is completed may impair outcomes, according to findings from the landmark N9831 trial. The findings were presented by Edith Perez, MD, director of the Breast Cancer Program at the Mayo Clinic, Jacksonville, Florida.
Results 161 - 170 of 173